Technical Analysis for RNXT - RenovoRx, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 1.26 | -6.67% | -0.09 |
RNXT closed down 6.67 percent on Friday, May 24, 2024, on 1.3 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Fell Below 200 DMA | Bearish | 0.00% | |
| Fell Below 50 DMA | Bearish | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | 0.00% | |
| New Downtrend | Bearish | 0.00% | |
| Expansion Pivot Sell Setup | Bearish Swing Setup | 0.00% | |
| NR7 | Range Contraction | -10.00% | |
| Narrow Range Bar | Range Contraction | -10.00% | |
| Inside Day | Range Contraction | -10.00% | |
| Gapped Up | Strength | -10.00% |
| Alert | Time |
|---|---|
| 50 DMA Support | 4 days ago |
| 200 DMA Support | 4 days ago |
| 60 Minute Opening Range Breakdown | 4 days ago |
| 1.5x Volume Pace | 4 days ago |
| Down 5% | 4 days ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trial for the locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Los Altos, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Solid Tumors Drugs Cancer Treatment Pancreatic Cancer Oncolytics Biotech Gastrointestinal Cancer Evofosfamide Gemcitabine
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Solid Tumors Drugs Cancer Treatment Pancreatic Cancer Oncolytics Biotech Gastrointestinal Cancer Evofosfamide Gemcitabine
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.29 |
| 52 Week Low | 0.5488 |
| Average Volume | 36,868 |
| 200-Day Moving Average | 1.28 |
| 50-Day Moving Average | 1.29 |
| 20-Day Moving Average | 1.33 |
| 10-Day Moving Average | 1.38 |
| Average True Range | 0.10 |
| RSI (14) | 44.75 |
| ADX | 25.93 |
| +DI | 15.13 |
| -DI | 20.81 |
| Chandelier Exit (Long, 3 ATRs) | 1.18 |
| Chandelier Exit (Short, 3 ATRs) | 1.44 |
| Upper Bollinger Bands | 1.50 |
| Lower Bollinger Band | 1.17 |
| Percent B (%b) | 0.28 |
| BandWidth | 25.02 |
| MACD Line | 0.02 |
| MACD Signal Line | 0.03 |
| MACD Histogram | -0.0071 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.49 | ||||
| Resistance 3 (R3) | 1.49 | 1.42 | 1.45 | ||
| Resistance 2 (R2) | 1.42 | 1.36 | 1.42 | 1.44 | |
| Resistance 1 (R1) | 1.34 | 1.33 | 1.31 | 1.34 | 1.42 |
| Pivot Point | 1.27 | 1.27 | 1.25 | 1.27 | 1.27 |
| Support 1 (S1) | 1.19 | 1.21 | 1.15 | 1.18 | 1.10 |
| Support 2 (S2) | 1.12 | 1.18 | 1.12 | 1.08 | |
| Support 3 (S3) | 1.04 | 1.12 | 1.07 | ||
| Support 4 (S4) | 1.03 |
